NeuBase Therapeutics, Inc. (NASDAQ:NBSE) is among the top gainers of the stock market today, skyrocketing 12.47% or (0.56 points) to $5.04 from its previous close of $4.48. Does this growth mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 205438 contracts so far this session. NBSE shares had a relatively better volume day versus average trading capacity of 167.06 thousand shares, but with a 11.24 million float and a 8.21% run over a week, it’s definitely worth keeping an eye on. NBSE share price has been trading recently between $4.17 and $4.73.
The shorts are running away from NeuBase Therapeutics, Inc. (NBSE) stock. The latest set of short interest data was released on 15 July 2019, and the numbers show a drop in short interest in NBSE shares. While short interest still represents only 1.68% of NBSE’s float, the number of shares shorted have fallen by -94734. The number of shares shorted fell to 189310 shares, down from 284044 shares during the preceding fortnight. With average daily trading volumes at 464622 shares, days to cover decreased to about 3.638371 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board” and dated July 30, 2019.
During the recent trading session for NeuBase Therapeutics, Inc. (NASDAQ:NBSE), the company witnessed their stock rise $0.8 over a week and surge $1.69 from the price 20 days ago. When compared to their established 52-week high of $6.28, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 09/10/18. The recent low of $1.6 stood for a -19.77% since 02/01/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 0.89 is also allocated to the stock. Since the beta is less than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for NeuBase Therapeutics, Inc., the two-week RSI stands at 64.43. This figure suggests that NBSE stock, for now, is neutral, meaning that the shares are stable in terms of price movement. The stochastic readings, on the other hand, based on the current NBSE readings is similarly very revealing as it has a stochastic reading of 40.65% at this stage. This figure means that NBSE share price today is being neutral.
Technical chart claims that NeuBase Therapeutics, Inc. (NBSE) would settle between $4.75/share to $5.02/share level. However, if the stock price goes below the $4.19 mark, then the market for NeuBase Therapeutics, Inc. becomes much weaker. If that happens, the stock price might even plunge as low as $3.9 for its downside target. The stock is currently in the green zone of MACD, with the indicator reading 0.34. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.